Bioline Rx Ltd - ADR
BLRX - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$8.71M
Close$
$-2.46
225.3% downside
Current Fair Value
225.3% downsideOvervalued by 225.3% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $8.71 Million |
|---|---|
| Enterprise Value | $12.02 Million |
| Earnings per Share | $-0.29 |
| Beta | 0.7 |
| Outstanding Shares | 4,441,345 |
Return
| Return on Equity | -111.99% |
|---|---|
| Return on Assets | -46.06% |
| Return on Invested Capital | -48.67% |
Valuation & Multiples
| P/E Ratio | -1.03 |
|---|---|
| PEG | 4.69 |
| Price to Sales | 1.96 |
| Price to Book Ratio | 0.65 |
| Enterprise Value to Revenue | 2 |
| Enterprise Value to EBIT | -1.25 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.66 |
| Debt to Equity | 0.58 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 31, 2026
EPS Estimate
$-0.15
Consensus analyst estimateRevenue Estimate
$500,000
Consensus analyst estimateNext Earnings Call
Expected Date
November 18, 2026
EPS Estimate
$-0.09
Consensus analyst estimateRevenue Estimate
$375,000
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.00%▼ 1.50% |
|---|---|
| Total Invested | $5▼ 100.00% |
| Investors Holding | 1▼ 14.00% |
About Bioline Rx Ltd
22 employees
CEO: Philip Serlin
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial f...